A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2018
At a glance
- Drugs LY 3214996 (Primary) ; Abemaciclib; Gemcitabine; Midazolam; Paclitaxel
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 12 Sep 2018 Planned End Date changed from 1 Jul 2020 to 13 Jul 2020.
- 12 Sep 2018 Planned primary completion date changed from 1 Jan 2020 to 13 Jan 2020.
- 05 Jul 2018 Planned number of patients changed from 136 to 252.